Marie-Alix Codet

2 papers in the library · 3 citations · publishing 2022-2024

Papers

Sort Most recent Most cited

Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray.

International Journal of Psychiatry in Clinical Practice June 1, 2024 Ludovic Samalin, Lila Mekaoui, Pierre De Maricourt et al. 3 citations

ESKALE is a French, multicentre, observational study of adults with treatment-resistant depression (TRD) treated with esketamine. This interim analysis describes baseline demographic and clinical characteristic evolution in patients included and treated from early access program to post-marketing launch. Data were collected from medical records and included patient characteristics, disease...

DOI: 10.1080/13651501.2024.2398788 Full text Esketamine Treatment-resistant depression Clinical profile Real-world experience +4

Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.

International Journal of Psychiatry in Clinical Practice November 2022 Ludovic Samalin, Maud Rothärmel, Lila Mekaoui et al.

To present the first real-world data of patients with treatment-resistant depression (TRD) treated with esketamine through a French cohort Temporary Authorisation for Use (ATUc) programme. In 2019, the French Health Authorities exceptionally granted the first ATUc in psychiatry for TRD patients. Clinical characteristics, safety and efficacy data were reported by physicians. The ATUc ended ∼6...

DOI: 10.1080/13651501.2022.2030757 Full text Esketamine Major depressive disorder Treatment-resistant depression Antidepressant +1